FrancophonIA/ELRC3.0 huggingface dataset:
English: If use is authorised in neonates and infants add the following statement]
Danish: Hvis anvendelse er godkendt til nyfødte skal følgende tilføjes]
English: LV - Latvia
Danish: Letland
English: There have been reports of nephrogenic systemic fibrosis (which causes hardening of the skin and may affect also soft tissue and internal organs) most of which were in patients who received {Invented name} together with other gadolinium-containing contrast agents.
Danish: Der er indberetninger om nefrogen systemisk fibrose (som kan medføre forhærdelse af huden og som også kan påvirke blødt væv og indre organer) hvoraf de fleste forekom hos patienter, som fik {Produktnavn} sammen med andre kontrastmidler, der indeholder gadolinium.
English: As kidney function is immature in infants up to 1 year of age, {Invented name} will only be used in patients 6 to 12 months of age after careful consideration by the doctor.
Danish: Da nyrefunktionen er umoden hos spædbørn i alderen op til 1 år, bør {Produktnavn} kun anvendes hos patienter i alderen 6 til 12 måneder efter nøje overvejelse af lægen.
English: [If use is not authorised in children under 2 years add the following statement]
Danish: [Tilføj følgende, hvis brugen ikke er godkendt til børn under 2 år]
English: RO-Romania
Danish: Rumænien
English: solution for injection (syringe)
Danish: Injektionsvæske, opløsning (syringe)
English: 4.2 Posology and method of administration [Use currently approved text with the addition of guidance for special populations (patients with renal impairment, neonates, infants and the elderly)]
Danish: [Anvend nuværende godkendt tekst med tilføjelse af vejledning for særlige populationer (patienter med nedsat nyrefunktion, nyfødte, spædbørn og ældre) ]
English: There have been reports of nephrogenic systemic fibrosis (which causes hardening of the skin and may affect also soft tissue and internal organs) in patients who received {Invented name} together with other gadolinium-containing contrast agents.
Danish: Der er indberetninger om nefrogen systemisk fibrose (som kan medføre forhærdelse af huden og som også kan påvirke blødt væv og indre organer) hos patienter, som fik {Produktnavn} sammen med andre kontrastmidler, der indeholder gadolinium.
English: There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR< 30ml/min /1.73 m2).
Danish: Der foreligger rapporter om nefrogen systemisk fibrose (NSF) relateret til brug af nogle gadoliniumholdige kontrastmidler hos patienter med akut eller kronisk alvorligt nedsat nyrefunktion (GFR< 30 ml/min/1,73 m2).
English: Isolated cases of nephrogenic systemic fibrosis (NSF) have been reported with {Invented name}, most of which were in patients co-administered other gadolinium-containing contrast agents (see section or
Danish: Der har været rapporteret enkeltstående tilfælde af nefrogen systemisk fibrose (NSF) ved anvendelse af {Produktnavn}, hvoraf de fleste forekom hos patienter, som samtidig har fået andre gadoliniumholdige kontrastmidler (se punkt 4.4).
English: DOTAREM 0,5 mmol/ml injection 20ml injection intravenous use
Danish: DOTAREM 0,5 mmol/ml injection 20ml
English: Isolated cases of nephrogenic systemic fibrosis (NSF) have been reported with {Invented name} in patients co-administered other gadolinium-containing contrast agents (see section 4.4).
Danish: Der har været rapporteret enkeltstående tilfælde af nefrogen systemisk fibrose (NSF) hos patienter, som samtidig har fået andre gadoliniumholdige kontrastmidler (se punkt 4.4).
English: Paediatric patients
Danish: Specielle patientgrupper
English: Gadovist 1.0 mmol/ml Solution for Injection in prefilled cartridge solution for injection, in prefilled cartridge intravenous use
Danish: Gadovist 1.0 mmol/ml Solution for Injection in prefilled cartridge
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SECTIONS OF THE PACKAGE LEAFLET FOR LOW RISK GADOLINIUM-CONTAINING CONTRAST AGENTS (gadoteric acid, gadoteridol, gadobutrol)
Danish: ÆNDRINGER DER SKAL TILFØJES UNDER DE RELEVANTE PUNKTER I INDLÆGSSEDLEN FOR LAV RISIKO GADOLINIUMHOLDIGE KONTRASTMIDLER (gadoterinsyre, gadoteridol, gadobutrol)
English: DOTAREM 0,5 mmol/ml injection 15ml injection intravenous use
Danish: DOTAREM 0,5 mmol/ml injection 15ml
English: Primovist 0.25 mmol/ml Sol for Injection, prefilled syringe solution for injection, prefilled syringe intravenous use
Danish: Primovist 0.25 mmol/ml Sol for Injection, prefilled syringe
English: Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, {Invented name} should only be used in these patients after careful consideration.
Danish: På grund af umoden nyrefunktion hos nyfødte i alderen op til 4 uger og spædbørn i alderen op til 1 år, bør {Produktnavn} kun anvendes hos disse patienter efter omhyggelig vurdering.
English: Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, {Invented name} should only be used in these patients after careful consideration at a dose not exceeding {X} mmol/kg body weight.
Danish: På grund af umoden nyrefunktion hos nyfødte i alderen op til 4 uger og spædbørn i alderen op til 1 år bør {Produktnavn} kun anvendes hos disse patienter efter omhyggelig vurdering og med en dosis, der ikke må overstige {x} mmol/kg legemsvægt.
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR LOW RISK GADOLINIUM-CONTAINING CONTRAST AGENTS (gadoteric acid, gadoteridol, gadobutrol)
Danish: ÆNDRINGER DER SKAL TILFØJES UNDER DE RELEVANTE PUNKTER I PRODUKTRESUMÉET FOR LAV RISIKO GADOLINIUMHOLDIGE KONTRASTMIDLER (gadoterinsyre, gadoteridol, gadobutrol)
English: Product name
Danish: DET SKAL DU VIDE OM [PRODUKTNAVN]
English: [If use is restricted for use in children greater than 1 year of age, specify the indication and age for which use is not recommended]
Danish: [Hvis anvendelse er begrænset til børn, der er ældre end 1 år, specificeres indikation og fra hvilken alder anvendelse frarådes]
English: DOTAREM 0,5 mmol/ml injection 60ml injection intravenous use
Danish: DOTAREM 0,5 mmol/ml injection 60ml
English: As kidney function is immature in babies up to 4 weeks of age and infants up to 1 year of age, {Invented name} will only be used in these patients after careful consideration by the doctor.
Danish: Da nyrefunktionen er umoden hos nyfødte i alderen op til 4 uger og spædbørn i alderen op til 1 år, bør {Produktnavn} kun anvendes hos disse patienter efter nøje overvejelse af lægen.
English: Due to immature renal function in infants up to 1 year of age, {Invented name} should only be used in these patients after careful consideration at a dose not exceeding {x} mmol/kg body weight.
Danish: Da spædbørn, der er op til 1 år gamle, har en umoden nyrefunktion, må {Særnavn} kun anvendes til disse patienter efter omhyggelig lægelig vurdering ved en dosis, der ikke overstiger {x} mmol/kg legemsvægt.
English: DOTAREM 0,5 mmol/ml injection 100ml injection intravenous use
Danish: DOTAREM 0,5 mmol/ml injection 100ml
English: Box 4220 Nydalen, N-0401 Oslo Norway
Danish: P.O. Box 4220 Nydalen, N-0401 Oslo Norway
English: Omniscan 0.5mmol/ml solution for injection, prefilled syringe solution for injection, prefilled syringe intravenous use
Danish: Omniscan 0.5mmol/ml solution for injection, prefilled syringe
English: There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of {Invented name} and some other gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR < 30 ml/min/1.73m2).
Danish: Der er set tilfælde af nefrogen systemisk fibrose (NSF ) i forbindelse med anvendelsen af {Særnavn} og nogle andre kontraststoffer, som indeholder gadolinium, hos patienter med akut eller kronisk svært nedsat nyrefunktion (GFR < 30 ml/min/1,73 m2).
English: [If use is permitted in infants, add a statement on use in infants]
Danish: [Tilføj en erklæring om brug til spædbørn, hvis brug til spædbørn er tilladt]
English: {Invented name} should not be used in newborn babies up to the age of 4 weeks.
Danish: {Særnavn} bør ikke bruges til nyfødte, der er op til 4 uger gamle.
English: LULuxembourg
Danish: Luxembourg
English: {Invented name} should not be given to newborn babies up to age of 4 weeks.
Danish: {Særnavn} bør ikke gives til nyfødte, der er op til 4 uger gamle.
English: [If use is restricted for use in children greater than 1 year of age, specify the indication and age at which use is not recommended]
Danish: [hvis anvendelse er begrænset til børn, der er ældre end 1 år, med specifikation af indikation og af hvilken alder, hvor anvendelse frarådes]
English: {Invented name} should also not be given to newborn babies up to age of 4 weeks.
Danish: {Særnavn} må heller ikke gives til nyfødte, der er op til 4 uger gamle.
English: Box 4220 Nydalen, Oslo N-0401
Danish: P.O. Box 4220 Nydalen, Oslo N-0401
English: [If use is permitted in neonates and infants, add a statement on use in neonates and infants]
Danish: [Tilføj angivelse om anvendelse til nyfødte og spædbørn, hvis anvendelse er tilladt til nyfødte og spædbørn ]
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR HIGH RISK GADOLINIUM-CONTAINING CONTRAST AGENTS (gadodiamide, gadopentetic acid)
Danish: ÆNDRINGER TIL RELEVANTE AFSNIT I PRODUKTRESUMEER FOR HØJRISIKO KONTRASTMIDLER, SOM INDEHOLDER GADOLINIUM (gadodiamid, gadopentetinsyre)
English: Gadovist 1.0 mmol/ml Solution for Injection in prefilled syringe solution for injection, in prefilled syringe intravenous use
Danish: Gadovist 1.0 mmol/ml Solution for Injection in prefilled syringe
English: Due to immature renal function in infants up to 1 year of age, {Invented name} should only be used in these patients after careful consideration.
Danish: Da spædbørn, der er op til 1 år gamle, har en umoden nyrefunktion, må {Særnavn} kun anvendes til disse patienter efter en omhyggelig vurdering.
English: IS - Iceland
Danish: Island
English: PL - Poland
Danish: Polen
English: Take special care with {Invented name}: [Use currently approved text with the addition of information on impaired renal function, use in neonates and infants and use in the elderly]
Danish: Lægen eller sundhedspersonalet vil være ekstra forsigtig med at behandle dig med {Produktnavn} [Anvend nuværende godkendt tekst med yderligere information om nedsat nyrefunktion, anvendelse til nyfødte og spædbørn samt anvendelse til ældre]
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SECTIONS OF THE PACKAGE LEAFLET FOR HIGH RISK GADOLINIUM-CONTAINING CONTRAST AGENTS (gadodiamide, gadopentetic acid)
Danish: ÆNDRINGER TIL RELEVANTE AFSNIT I INDLÆGSSEDLER FOR HØJRISIKO KONTRASTMIDLER, SOM INDEHOLDER GADOLINIUM (gadodiamid, gadopentetinsyre)
English: solution for injection, pre-filled syringe intravenous use
Danish: Injektionsvæske, opløsning Injektionssprøjte og Cylinderampul
English: Solution for injection (pre-filled syringe)
Danish: Injektionsvæske, opløsning (Fyldt injektionssprøjte)
English: BE - Belgium
Danish: Belgien
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MEDIUM RISK GADOLINIUM-CONTAINING CONTRAST AGENTS (gadoxetic acid, gadobenic acid)
Danish: ÆNDRINGER DER SKAL TILFØJES UNDER DE RELEVANTE PUNKTER I PRODUKTRESUMÉET FOR MIDDEL RISIKO GADOLINIUMHOLDIGE KONTRASTMIDLER (gadoxetinsyre, gadobensyre)
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SECTIONS OF THE PACKAGE LEAFLET FOR MEDIUM RISK GADOLINIUM-CONTAINING CONTRAST AGENTS (gadoxetic acid, gadobenic acid)
Danish: ÆNDRINGER DER SKAL TILFØJES UNDER DE RELEVANTE PUNKTER I INDLÆGSSEDLEN FOR MIDDEL RISIKO GADOLINIUMHOLDIGE KONTRASTMIDLER (gadoxetinsyre, gadobensyre)
English: 4.4 Special warnings and precautions for use [With the exception of information on impaired renal function, use in neonates and infants and use in the elderly, use currently approved text]
Danish: [Anvend nuværende godkendt tekst bortset fra information om nedsat nyrefunktion, anvendelse hos nyfødte og spædbørn samt anvendelse til ældre]
English: Solution for injection, pre-filled syringe intravenous use
Danish: Injektionsvæske, opløsning, Fyldt cylinderampul
English: 6.6 Special precautions for disposal and other handling [Use currently approved text for information on disposal]
Danish: [Anvend gældende godkendt tekst for oplysninger om bortskaffelse]
English: BACKGROUND INFORMATION *
Danish: BAGGRUNDSOPLYSNINGER*
English: This review was finalised in June 2006.
Danish: Denne gennemgang blev afsluttet i juni 2006.
English: The Member states competent Authorities will continue to keep the product under regular review.
Danish: Medlemsstaternes kompetente myndigheder fører fortsat løbende opsyn med produktet.
English: The final opinion was converted into a Decision by the European Commission on 7 September 2007.
Danish: Den endelige udtalelse blev konverteret til en afgørelse truffet af Europa-Kommissionen den 7. september 2007.
English: This review, which concluded in October 2005, did not reveal any new safety concerns for the class of NSAIDs as a whole.
Danish: Denne gennemgang, der sluttede i oktober 2005, gav ikke anledning til nye sikkerhedsmæssige betænkeligheder for klassen af NSAID som helhed.
English: Piroxicam is authorised in the European Union following national marketing procedures.
Danish: Piroxicam er godkendt i EU efter nationale procedurer.
English: The Rapporteur and Co-Rapporteur appointed were Dr Rossi and Dr Calvo-Rojas respectively.
Danish: Som rapportør og medrapportør udpegedes henholdsvis dr. Rossi og dr. Calvo-Rojas.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 31(2) REFERRAL
Danish: UDTALELSE FRA UDVALGET FOR HUMANMEDICINSKE LÆGEMIDLER (CHMP) EFTER EN INDBRINGELSE I HENHOLD TIL ARTIKEL 31, STK. 2, FOR
English: On 2 August 2006, the European Commission referred the matter to the EMEA under Article 31 of Directive 2001/83/EC, as amended, for piroxicam containing medicinal products.
Danish: Den 2. august 2006 indbragte Europa-Kommissionen sagen for EMEA i henhold til artikel 31 i Rådets direktiv 2001/83/EF, med senere ændringer, for lægemidler indeholdende piroxicam.
English: International Non-Proprietary Name (INN): piroxicam
Danish: Internationalt fællesnavn (INN): piroxicam
English: ∗ Notes: the information given in this document and annexes reflects only the CHMP Opinion dated 21 June 2007.
Danish: ∗ Bemærkninger: oplysningerne i dette dokument og i bilagene afspejler alene CHMP's udtalelse dateret 21 juni 2007.
English: PIROXICAM CONTAINING MEDICINAL PRODUCTS
Danish: LÆGEMIDLER INDEHOLDENDE PIROXICAM
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended product information in Annex III and the conditions of the Marketing Authorisation in Annex IV.
Danish: Listen over de berørte produktnavne findes i bilag I. De faglige konklusioner fremgår af bilag II, det ændrede produktresumé af bilag III, og vilkårene for markedsføringstilladelsen af bilag IV.
English: London, 20 September 2007 EMEA/380917/2007
Danish: London, den 20. september 2007 EMEA/470112/2007
English: Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties.
Danish: Piroxicam er et non-steroidt antiinflammatorisk lægemiddel (NSAID), der virker antiinflammatorisk, analgetisk og antipyretisk.
English: The referral procedure started on the 21 September 2006.
Danish: Behandlingen af indbringelsen begyndte den 21. september 2006.
English: Further to a request from the European Commission the CHMP reviewed safety data on non-selective NSAIDs.
Danish: På foranledning af Europa-Kommissionen gennemgik CHMP de foreliggende oplysninger om sikkerheden af ikke-selektive NSAID.
English: The CHMP considered that the assessment raised concerns on the benefit/risk balance of piroxicam and informed the European Commission accordingly.
Danish: CHMP fandt, at vurderingen gav anledning til betænkelighed vedrørende risk/benefit forholdet for piroxicam, og underrettede Europa-Kommissionen herom.
English: Based on the available data the CHMP considered that the benefit/risk balance for systemic formulations of piroxicam is positive in the treatment of symptomatic relief of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis; however the CHMP considered that the benefit/risk balance of piroxicam in the treatment of acute conditions is negative and that these indications should be revoked.
Danish: På baggrund af de foreliggende oplysninger fandt CHMP, at risk/benefit forholdet for systemiske formuleringer af piroxicam er positivt til symptomlindring ved osteoartritis, reumatoid artritis og ankyloserende spondylitis; CHMP fandt imidlertid, at risk/benefit forholdet for piroxicam til behandling af akutte tilstande er negativt, og at disse indikationer bør slettes.
English: The reasons for referral concerned the risk of gastrointestinal and skin reactions.
Danish: Begrundelsen for indbringelsen vedrørte risikoen for gastrointestinale reaktioner og hudreaktioner.
English: The review found that limited epidemiological data and spontaneous adverse drug reaction data provided a signal of increased risk of gastrointestinal and skin reactions (including life-threatening bullous reactions) for piroxicam relative to other non-selective NSAIDs.
Danish: Ved gennemgangen fandtes de begrænsede epidemiologiske data og oplysninger fra spontane bivirkningsindberetninger at pege på, at der er større risiko for gastrointestinale reaktioner og hudreaktioner (herunder livstruende bulløse reaktioner) for piroxicam end for andre ikke-selektive NSAID.
English: Written explanations were provided by the Marketing Authorisation Holders (MAH) on 18 December 2006 and 13 April 2007.
Danish: Indehaverne af markedsføringstilladelserne indsendte skriftlige redegørelser den 18. december 2006 og den 13. april 2007, og afgav mundtlige forklaringer til CHMP den 22. og 23. maj 2007.
English: A number of restrictions on use, contraindications and strengthened warnings have been added to the Summary Product Characteristics and Package Leaflet in relation to gastrointestinal and skin safety.
Danish: I produktresuméet og indlægssedlen er der tilføjet en række begrænsninger i anvendelsen, kontraindikationer og skærpede advarsler vedrørende den gastrointestinale sikkerhed og hudreaktioner.
English: However a need to further evaluate the benefit/risk balance of some non-selective NSAIDs including piroxicam was identified.
Danish: For visse ikke-selektive NSAID, herunder piroxicam, blev der imidlertid fundet behov for en yderligere vurdering af risk/benefit forholdet.
English: Treatment can be repeated once a month.
Danish: Behandlingen kan gentages en gang om måneden.
English: These usually disappear within 24 hours after administration.
Danish: Disse svinder sædvanligvis i løbet af 24 timer efter påføringen.
English: Children must not handle treated dogs for at least four hours after application of the veterinary medicine.
Danish: Børn må ikke komme i berøring med behandlede hunde i mindst fire timer efter påføringen af veterinærlægemidlet.
English: Vectra 3D received a marketing authorisation valid throughout the EU on 4 December 2013.
Danish: Vectra 3D modtog en markedsføringstilladelse med gyldighed i hele EU den 4. december 2013.
English: This means that they kill parasites that come into contact with the skin or fur of animals, such as fleas, ticks or flying insects.
Danish: Det vil sige, at de dræber parasitter, der kommer i kontakt med dyrets hud eller pels, såsom lopper, flåter eller flyvende insekter.
English: Its actions last for up to a month, and it prevents fleas from hatching and developing for two months.
Danish: Dets virkning varer op til en måned, og det forhindrer udklækning og udvikling af lopper i to måneder.
English: Further information on Vectra 3D can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/vectra-3d.
Danish: Yderligere oplysninger om Vectra 3D findes på agenturets websted under: ema.europa.eu/medicines/veterinary/EPAR/vectra-3d.
English: Treated dogs should not be permitted to sleep with their owners, especially children, on the day of treatment.
Danish: På behandlingsdagen må hunden ikke sove sammen med sin ejer, navnlig børn.
English: Other information about Vectra 3D
Danish: Andre oplysninger om Vectra 3D
English: Vectra 3D must not be used on cats and they must not be allowed to groom dogs recently treated with the medicine, as it may cause harmful effects that could be fatal.
Danish: Vectra 3D må ikke anvendes til katte, og de må ikke soignere hunde, som for nylig er behandlet med lægemidlet, da dette kan medføre skadelige virkninger, der kan være dødelige.
English: The effectiveness of Vectra 3D against fleas, ticks, mosquitoes and flies was investigated in 24 laboratory studies and in two field studies.
Danish: Virkningen af Vectra 3D mod lopper, flåter, myg og fluer blev undersøgt i 24 laboratoriestudier og to feltstudier.
English: The application site should be allowed to dry before the dog is allowed to come into contact with fabrics or furnishings.
Danish: Påføringsstedet bør tørre, før hunden kommer i kontakt med tekstiler eller møbler.
English: The European Medicines Agency decided that Vectra 3D's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur besluttede, at fordelene ved Vectra 3D opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: The active substances in Vectra 3D act as ‘ectoparasiticides'.
Danish: De aktive stoffer i Vectra 3D virker som "ektoparasiticider".
English: The content of one full Vectra 3D applicator is applied directly to the dog's skin, after parting its fur, either in one or more spots on the back, depending on the dog's weight, or in a continuous line along the centre of the back from the base of the tail to the shoulder blades.
Danish: Indholdet af én fuld Vectra 3D-applikator påføres direkte på hundens hud efter deling af pelsen, enten på et enkelt eller flere punkter på ryggen, afhængigt af hundens vægt, eller langs en linje midt på ryggen fra haleroden til skulderbladene.
English: People applying the medicine should not smoke, eat or drink and should wash their hands thoroughly after handling the product.
Danish: Ved påføring af lægemidlet bør rygning og indtagelse af mad og drikke undgås, og efter håndtering af produktet vaskes hænderne grundigt.
English: If skin or eye irritation persists, or if the veterinary medicine is accidentally swallowed, immediate medical advice should be sought and the package leaflet or label shown to the doctor.
Danish: Ved vedvarende hud- eller øjenirritation, eller hvis lægemidlet utilsigtet indtages, bør der straks søges lægehjælp, og indlægssedlen eller etiketten skal vises til lægen.
English: Dinotefuran and permethrin are insecticides which kill insects by acting on their nervous system by different mechanisms; permethrin also acts similarly on ticks.
Danish: Dinotefuran og permethrin er insekticider, der dræber insekter ved at påvirke deres nervesystem ved forskellige mekanismer; permethrin virker på lignende måde på flåter.
English: The first field study involved 485 dogs with flea and/or tick infestations.
Danish: Det første feltstudie omfattede 485 hunde med angreb af lopper og/eller flåter.
English: An overview of Vectra 3D and why it is authorised in the EU
Danish: Oversigt over Vectra 3D, og hvorfor det er godkendt i EU
English: Vectra 3D is a veterinary medicine used on dogs to treat and prevent flea and tick infestations and to repel sand flies, mosquitoes and stable flies.
Danish: Vectra 3D er et lægemiddel til dyr, som anvendes hos hunde til behandling og forebyggelse af angreb af lopper og flåter og til at afvise sandfluer, myg og staldfluer.